DE69225978T2 - Verfahren zur herstellung und anwendung von multimeren hämoblobinen - Google Patents

Verfahren zur herstellung und anwendung von multimeren hämoblobinen

Info

Publication number
DE69225978T2
DE69225978T2 DE69225978T DE69225978T DE69225978T2 DE 69225978 T2 DE69225978 T2 DE 69225978T2 DE 69225978 T DE69225978 T DE 69225978T DE 69225978 T DE69225978 T DE 69225978T DE 69225978 T2 DE69225978 T2 DE 69225978T2
Authority
DE
Germany
Prior art keywords
multimeral
hemoblobines
production
cysteines
artificial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69225978T
Other languages
English (en)
Other versions
DE69225978D1 (de
Inventor
David Anderson
Anthony Mathews
Gary Stetler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Biotech Technology SARL
Original Assignee
SOMATOGEN Inc BOULDER US
Somatogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOMATOGEN Inc BOULDER US, Somatogen Inc filed Critical SOMATOGEN Inc BOULDER US
Publication of DE69225978D1 publication Critical patent/DE69225978D1/de
Application granted granted Critical
Publication of DE69225978T2 publication Critical patent/DE69225978T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
DE69225978T 1991-11-08 1992-11-06 Verfahren zur herstellung und anwendung von multimeren hämoblobinen Expired - Fee Related DE69225978T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/789,179 US5545727A (en) 1989-05-10 1991-11-08 DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
PCT/US1992/009752 WO1993009143A1 (en) 1991-11-08 1992-11-06 Production and use of multimeric hemoglobins

Publications (2)

Publication Number Publication Date
DE69225978D1 DE69225978D1 (de) 1998-07-23
DE69225978T2 true DE69225978T2 (de) 1999-02-11

Family

ID=25146814

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69225978T Expired - Fee Related DE69225978T2 (de) 1991-11-08 1992-11-06 Verfahren zur herstellung und anwendung von multimeren hämoblobinen

Country Status (13)

Country Link
US (7) US5545727A (de)
EP (2) EP0611376B1 (de)
JP (1) JPH07501059A (de)
AT (1) ATE167485T1 (de)
AU (1) AU672960B2 (de)
CA (1) CA2121889C (de)
DE (1) DE69225978T2 (de)
FI (1) FI942138A (de)
HU (1) HUT70309A (de)
IL (2) IL119656A0 (de)
NO (1) NO941703L (de)
SG (1) SG47882A1 (de)
WO (1) WO1993009143A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5844090A (en) 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
US6828125B1 (en) * 1989-05-10 2004-12-07 Baxter Biotech Technology, S.A.R.L. DNA encoding fused di-alpha globins and use thereof
US6150506A (en) * 1989-05-10 2000-11-21 Baxter Biotech Technology Sarl Modified hemoglobin-like compounds and methods of purifying same
US5599907A (en) * 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
ATE168014T1 (de) * 1991-11-08 1998-07-15 Somatogen Inc Hämoglobine als arzneimittelabgabesystem
US6610654B2 (en) 1993-03-31 2003-08-26 Wellstat Therapeutics Corporation Inhibitor of stem cell proliferation and uses thereof
US5939391A (en) * 1993-03-31 1999-08-17 Pro-Neuron, Inc. Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
JPH08510997A (ja) * 1993-03-31 1996-11-19 プロ−ニューロン，インコーポレイテッド 幹細胞増殖インヒビターおよびその使用
IS4198A (is) * 1993-08-13 1995-02-14 Somatogen, Inc Meðferð vegna aukaverkana sem tengjast gjöf á utanfrumublóðrauða
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6218513B1 (en) 1995-12-22 2001-04-17 Baxter Biotech Technology Sarl Globins containing binding domains
WO1997023631A2 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
AU3904497A (en) 1996-08-02 1998-02-25 Somatogen, Inc. Methods of controlling beta dimer formation in hemoglobin
WO1998013386A1 (en) * 1996-09-27 1998-04-02 The Board Of Trustees Of The University Of Illinois Oxygen-binding heme proteins incorporating circularly-permuted globins
AU4990697A (en) * 1996-10-18 1998-05-15 Eli Lilly And Company Methods of reducing the levels of protoporphyrin ix in recombinant hemoglobin preparations
US6558671B1 (en) 1997-01-30 2003-05-06 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
DE69831248T2 (de) * 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
EP1950298A3 (de) 1997-05-02 2008-12-24 Baxter Biotech Technology S.A.R.L. Hämoglobinmutanten mit erhöhtem Löslichkeitswert und/oder reduzierter Stickoxidspülung
AU750295B2 (en) 1997-05-02 2002-07-11 Baxter Biotech Technology S.A.R.L. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
US6780892B1 (en) 1998-10-01 2004-08-24 Temple University—Of the Commonwealth System of Higher Education Polymeric hemoglobin mutants
CA2344604A1 (en) * 1998-10-01 2000-04-06 Temple University - Of The Commonwealth System Of Higher Education Polymeric hemoglobin mutants
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1233986A4 (de) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl Hämoglobin-zusammensetzungen mit verminderten nebeneffekten
US7164035B2 (en) * 2000-01-07 2007-01-16 Newsome David A Zinc-monocysteine complex and method of using zinc-cysteine complexes
CA2417214C (en) * 2000-08-03 2016-06-21 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US6645767B1 (en) * 2000-10-03 2003-11-11 Carnegie Mellon University Cells engineered to contain genes of interest without expressed bacterial sequences and materials and methods therefor
US8008459B2 (en) * 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
WO2002061113A2 (en) * 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
IL157378A0 (en) * 2001-03-09 2004-02-19 Genentech Inc Process for production of polypeptides
US20040133468A1 (en) * 2002-04-12 2004-07-08 Varghese Kivin G. Method and system for providing interactive adversing cross reference to related application
US7238777B2 (en) * 2001-10-16 2007-07-03 Asahi Kasei Kabushiki Kaisha Agents for adsorption and bridging for adenovirus
EP1431244A4 (de) 2001-11-08 2004-08-04 Matsushita Electric Ind Co Ltd Mikrokornfolie und verfahren zur herstellung derselben
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
CN1761524B (zh) * 2002-07-22 2012-03-21 Mba聚合物公司 介质调节静电分离
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
AU2003300139B2 (en) 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005040395A1 (en) 2003-10-22 2005-05-06 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
WO2005074521A2 (en) * 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
JP2008528004A (ja) * 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン
WO2006089206A2 (en) * 2005-02-16 2006-08-24 Massachusetts Institute Of Technology Methods to enhance carbon monoxide dehydrogenase activity and uses thereof
US8318474B1 (en) * 2005-05-23 2012-11-27 California Institute Of Technology Engineered yeast cells and uses thereof
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
JP2011504722A (ja) * 2007-08-21 2011-02-17 モルフォシス・アー・ゲー ジスルフィド結合形成のための改良された方法
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
WO2011146833A1 (en) 2010-05-20 2011-11-24 Evolva Inc. Method of producing isoprenoid compounds in yeast
WO2012012352A2 (en) * 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
CN112662677B (zh) * 2021-03-02 2022-12-02 天津师范大学 一组红裸须摇蚊Hb基因及其在水质生物监测中的应用
CN113087787B (zh) * 2021-05-19 2023-03-21 广西医科大学第二附属医院(广西医科大学第二临床医学院) 一种蚯蚓血红蛋白分离及纯化方法
WO2023102156A1 (en) 2021-12-03 2023-06-08 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same
CN116203144B (zh) * 2022-05-11 2023-10-27 重庆医科大学附属儿童医院 测定血红蛋白中各型珠蛋白链比率的方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2449885C3 (de) * 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4738952A (en) * 1984-04-27 1988-04-19 Synthetic Blood Corporation Substitute for human blood and a method of making the same
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
DE3515252C2 (de) * 1985-04-27 1994-02-24 Roehm Gmbh Verfahren zur Immobilisierung gelöster Eiweißstoffe
EP0206448B1 (de) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4730936A (en) * 1986-10-10 1988-03-15 The United States Of America As Represented By The Secretary Of The Air Force Gas driven system for preparing large volumes of non-oxidized, pyridoxylated, polymerized stroma-free hemoglobin solution for use as a blood substitute
DE3636590A1 (de) * 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
WO1988006601A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Gene repressors
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5049493A (en) * 1987-10-23 1991-09-17 California Institute Of Technology Enhancement of cell growth by expression of a cloned hemoglobin gene
EP0319206A3 (de) * 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gen-Vermehrung
IL87708A (en) * 1988-09-08 1994-04-12 Technion Inst For Research And Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof
ES2204926T3 (es) * 1989-05-10 2004-05-01 Baxter Biotech Technology S. .R.L. Procedimiento de preparacion de hemoglobina y derivados de hemoglobina a partir de manipulacion de bacterias y levaduras.
NL8901174A (nl) * 1989-05-10 1990-12-03 Het Hoofd Van De Afdeling Mili Hemoglobine-preparaat en gebruik daarvan.
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
NZ237827A (en) * 1990-04-16 1994-03-25 Strohtech Inc Pure globin chain or haem-binding fragment thereof and methods for its production
WO1992011283A1 (en) * 1990-12-20 1992-07-09 The University Of Alabama Research Foundation Transgenic, cross-linked hemoglobin
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation

Also Published As

Publication number Publication date
US5801019A (en) 1998-09-01
WO1993009143A1 (en) 1993-05-13
US5844088A (en) 1998-12-01
US5744329A (en) 1998-04-28
NO941703D0 (no) 1994-05-06
JPH07501059A (ja) 1995-02-02
CA2121889C (en) 2001-08-21
AU672960B2 (en) 1996-10-24
DE69225978D1 (de) 1998-07-23
IL119656A0 (en) 1997-02-18
EP0611376A1 (de) 1994-08-24
SG47882A1 (en) 1998-04-17
IL119657A0 (en) 1997-02-18
US5844089A (en) 1998-12-01
HUT70309A (en) 1995-09-28
EP0611376B1 (de) 1998-06-17
FI942138A (fi) 1994-06-29
CA2121889A1 (en) 1993-05-13
ATE167485T1 (de) 1998-07-15
AU3133793A (en) 1993-06-07
HU9401338D0 (en) 1994-08-29
EP0857489A3 (de) 1998-09-30
US6274331B1 (en) 2001-08-14
EP0857489A2 (de) 1998-08-12
US5798227A (en) 1998-08-25
FI942138A0 (fi) 1994-05-09
NO941703L (no) 1994-07-04
US5545727A (en) 1996-08-13

Similar Documents

Publication Publication Date Title
DE69225978D1 (de) Verfahren zur herstellung und anwendung von multimeren hämoblobinen
DE3382190D1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE69233204D1 (de) Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
ATE176924T1 (de) Verfahren zur herstellung von menschlicher dnase
DE68904986T2 (de) Verfahren zur herstellung von 1,1,1-trifluor-2,2-dichlorethan.
DE69526861T2 (de) Linse zur korrektur von fehlsichtigkeiten aus polyersterharz mit hohem brechungsindex, erhöhter optischer uniformität und/oder verbesserter einfärbbarkeit
DE3750342T2 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE68907258D1 (de) Verfahren zur herstellung von perfluorierten copolymeren.
ATE131876T1 (de) Verfahren zur herstellung von proteinen durch verwendung von cks-fusionsproteinen
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
DE69325452T2 (de) Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
DE58902137D1 (de) Verfahren zur herstellung von caprolacton.
DE58901829D1 (de) Verfahren zur herstellung von zeolithen.
DE68911680D1 (de) Verfahren zur herstellung von copolyarylensulfiden mit verwendung eines sauerstoffhaltigen gases.
DK313389A (da) Fremgangsmaade til opdraet af fisk og apparat til anvendelse derved
DE68900211D1 (de) Verfahren zur herstellung von 4,4'-dihydroxydiphenylmethan.
ATE125298T1 (de) Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression.
AT364813B (de) Verfahren zur herstellung von alpha-aryl-alpha, alpha-di(omega-aminoalkyl)acetamiden mit disubstituierter aminogruppe
DE3861262D1 (de) Verfahren zur herstellung von polysulfurierten olefin-zusammensetzungen mit hohem schwefel-und sehr niedrigem chlorgehalt.
DE68901559D1 (de) Verfahren und mittel zur augenanaesthesie unter verwendung von rodocain.
DE68905264T2 (de) Verfahren zur herstellung von proteoliposomen und verfahren zur herstellung von riesenproteoliposomen.
DE58903321D1 (de) Substituierte bisacyloxynaphtacene und verfahren zur herstellung von tetrathiotetracenen.
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
DE68902379D1 (de) Verfahren zur herstellung von verbessertem proteinhydrolysat.
DE58902422D1 (de) Verfahren zur herstellung von ethylen/acrylnitril-copolymerisaten, neue ethylen/acrylnitril-copolymerisate und ihre verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAXTER BIOTECH TECHNOLOGY S.A.R.L., NEUCHATEL, CH

8339 Ceased/non-payment of the annual fee